Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 22/11/2020
SIETES contiene 93161 citas

 
 
 1 a 20 de 6319 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Sun JW, Hernández-Díaz S, Haneuse S, Bourgeois FT, Vine SM, Olfson M, Bateman BT, Huybrechts KF. Association of selective serotonin reuptake inhibitors with the risk of type 2 diabetes in children and adolescents. JAMA Psychiatry 2020:1. [Ref.ID 103710]
3. Cita con resumen
Blotière P-O, Miranda S, Weill A, Mikaeloff Y, Peyre H, Ramus F, Zureik M, Coste J, Dray-Spira R. Risk of early neurodevelopmental outcomes associated with prenatal exposure to the antiepileptic drugs most commonly used during pregnancy: a French nationwide population-based cohort study. BMJ Open 2020;10:e034829. [Ref.ID 103654]
4. Cita con resumen
Anónimo. Domperidona*: supresión de la indicación en pediatría y recordatorio de las contraindicaciones en adultos y adolescentes. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2020;Referencia: MUH (FV), 3/2020:24 de febrero. [Ref.ID 103639]
5. Cita con resumen
Anónimo. In brief: Neuropsychiatric events with montelukast. Med Lett Drugs Ther 2020;62:65. [Ref.ID 103638]
6. Cita con resumen
Bunyavanich S, Vicencio A. Nasal gene expression of angiotensin-converting enzyme 2 in children and adults. JAMA 2020:1. [Ref.ID 103625]
8. Cita con resumen
Janiri D, Doucet GE, Pompili M, Sani G, Luna B, Brent DA, Frangou S. Risk and protective factors for childhood suicidality: a US population-based study. The Lancet Psychiatry 2020:12 de marzo. [Ref.ID 103552]
9. Cita con resumen
Geldhof A, Slater J, Clark M, Chandran U, Coppola D. Exposure to infliximab during pregnancy: post-marketing experience. Drug Saf 2020;43:febrero. [Ref.ID 103539]
10. Cita con resumen
Zernikow B. Can we really stop pediatric migraine?using network meta-analysis to remove the guess work. JAMA Pediatrics 2020:10 de febrero. [Ref.ID 103528]
11. Cita con resumen
Locher C, Kossowsky J, Koechlin H, Lam TL, Barthel J, Berde CB, Gaab J, Schwarzer G, Linde K, Meissner K. Efficacy, safety, and acceptability of pharmacologic treatments for pediatric migraine prophylaxis. A systematic review and network meta-analysis. JAMA Pediatrics 2020:10 de febrero. [Ref.ID 103527]
12. Cita con resumen
Blotière P-O, Raguideau F, Weill A, Elefant E, Perthus I, Goulet V, Rouget F, Zureik M, Coste J, Dray-Spira R. Risks of 23 specific malformations associated with prenatal exposure to 10 antiepileptic drugs. Neurology 2019;93:. [Ref.ID 103248]
14.Enlace a cita original Cita con resumen
. Roche pays $1.15bn for Sarepta’s Duchenne gene therapy. PMLiVE 2019:23 de diciembre. [Ref.ID 103235]
15. Cita con resumen
Taylor P. FDA grants surprise OK to Sarepta’s DMD therapy after earlier rejection. PMLiVE 2019:13 de diciembre. [Ref.ID 103233]
16.Enlace a cita original Cita con resumen
Castells M, Khan DA, Phillips EJ. Penicillin allergy. N Engl J Med 2019;381:12 de diciembre. [Ref.ID 103229]
17. Cita con resumen
Dalsgaard S, Thorsteinsson E, Trabjerg BB, Schullehner J, Plana-Ripoll O, Brikell I, Wimberley T, Thygesen M, Bang Madsen K, Timmerman A, Schendel D, McGrath JJ, Mortensen PB, Pedersen CB. Incidence rates and cumulative incidences of the full spectrum of diagnosed mental disorders in childhood and adolescence. JAMA Psychiatry 2019:20 de noviembre. [Ref.ID 103222]
18. Cita con resumen
Ji Y, Azuine RE, Zhang Y, Hou W, Hong X, Wang G, Riley A, Pearson C, Zuckerman B, Wang X. Association of cord plasma biomarkers of in utero acetaminophen exposure with risk of attention-deficit/hyperactivity disorder and autism spectrum disorder in childhood. JAMA Psychiatry 2019:30 de octubre. [Ref.ID 103208]
20.Enlace a cita original Cita con resumen
Waxmonsky JG, Pelham W 3rd, Campa A, Waschbusch DA, Li T, Marshall R, Babocsai L, Humphery H, Gnagy E, Swanson J, Hanc T, Fallahazad N, Pelham WE 4th. A randomized controlled trial of interventions for growth suppression in children with attention-deficit/hyperactivity disorder treated with central nervous system stimulants. J Am Acad Child Adolesc Psychiatry 2019:29 de agosto. [Ref.ID 103191]
Seleccionar todas
 
 1 a 20 de 6319 siguiente >>